MSK and OpenEvidence have announced a new partnership to advance precision oncology by integrating OpenEvidence into MSK’s clinical workflow and expanding access to OncoKB™, MSK’s FDA-recognized precision oncology knowledge base, for providers nationwide. Together, the collaboration aims to deliver AI-powered clinical insights and support more informed decision-making in complex cancer care.